Found: 24
Select item for more details and to access through your institution.
A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
How Does a Patient's Primary Renal Disease Impact Chronic Dialysis Management?
- Published in:
- Seminars in Dialysis, 2015, v. 28, n. 5, p. 470, doi. 10.1111/sdi.12397
- By:
- Publication type:
- Article
How Does a Patient's Primary Renal Disease Impact Chronic Dialysis Management?: Patients with Autosomal Dominant Polycystic Kidney Disease.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
- Published in:
- Kidney International, 2015, v. 88, n. 1, p. 17, doi. 10.1038/ki.2015.59
- By:
- Publication type:
- Article
Analysis of baseline parameters in the HALT polycystic kidney disease trials.
- Published in:
- Kidney International, 2012, v. 81, n. 6, p. 577, doi. 10.1038/ki.2011.411
- By:
- Publication type:
- Article
The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.
- Published in:
- 2017
- By:
- Publication type:
- journal article
What Is Autosomal Dominant Polycystic Kidney Disease?
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 329, n. 13, p. 1128, doi. 10.1001/jama.2023.2161
- By:
- Publication type:
- Article
Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review.
- Published in:
- PLoS ONE, 2021, v. 16, n. 5, p. 1, doi. 10.1371/journal.pone.0252479
- By:
- Publication type:
- Article
Implications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-61303-9
- By:
- Publication type:
- Article
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification.
- Published in:
- Annals of Internal Medicine, 2003, v. 139, n. 2, p. 137, doi. 10.7326/0003-4819-139-2-200307150-00013
- By:
- Publication type:
- Article
Living donor transplantation: Should we advocate for it?
- Published in:
- Nephrology News & Issues, 2014, v. 28, n. 2, p. 22
- By:
- Publication type:
- Article
Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report.
- Published in:
- Clinical Kidney Journal, 2022, v. 15, n. 3, p. 407, doi. 10.1093/ckj/sfab110
- By:
- Publication type:
- Article
Identifying patient‐important outcomes in polycystic kidney disease: An international nominal group technique study.
- Published in:
- Nephrology, 2019, v. 24, n. 12, p. 1214, doi. 10.1111/nep.13566
- By:
- Publication type:
- Article
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
- Published in:
- Nephrology Dialysis Transplantation, 2018, v. 33, n. 3, p. 477, doi. 10.1093/ndt/gfx043
- By:
- Publication type:
- Article
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
- Published in:
- Nephrology Dialysis Transplantation, 2017, v. 32, n. 11, p. 1857, doi. 10.1093/ndt/gfw294
- By:
- Publication type:
- Article
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.
- Published in:
- Nephrology Dialysis Transplantation, 2017, v. 32, n. 6, p. 969, doi. 10.1093/ndt/gfw060
- By:
- Publication type:
- Article
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
- Published in:
- Nephrology Dialysis Transplantation, 2016, v. 31, n. 11, p. 1887, doi. 10.1093/ndt/gfv422
- By:
- Publication type:
- Article
Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.
- Published in:
- Nephrology Dialysis Transplantation, 2011, v. 26, n. 8, p. 2515, doi. 10.1093/ndt/gfq806
- By:
- Publication type:
- Article
Diet, Indicators of Kidney Disease, and Later Mortality among Older Persons in the NHANES I Epidemiologic Follow-Up Study.
- Published in:
- American Journal of Public Health, 1994, v. 84, n. 8, p. 1299, doi. 10.2105/AJPH.84.8.1299
- By:
- Publication type:
- Article
Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.
- Published in:
- ClinicoEconomics & Outcomes Research, 2015, v. 7, p. 123, doi. 10.2147/CEOR.S75523
- By:
- Publication type:
- Article
The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.
- Published in:
- Kidney International, 2005, v. 67, n. 1, p. 265, doi. 10.1111/j.1523-1755.2005.00077.x
- By:
- Publication type:
- Article
Extrarenal manifestations of ADPKD.
- Published in:
- 1997
- By:
- Publication type:
- Case Study
Means of clinical evaluation of renal disease progression.
- Published in:
- Kidney International Supplement, 1992, n. 36, p. S-26, doi. 10.1111/1523-1755.ep15066535
- By:
- Publication type:
- Article